Phase 1 clinical trials targeting CD123 in AML using neutralizing mAbs and cytotoxic proteins fused to IL-3 cytokine or IL3Rα showed limited therapeutic efficiency [42–44], but establishing CD123-specific CAR T cell therapy has the potential to target AML LSCs and improve survival [25]. Here, IL3RA is linked to acute myeloid leukemia.